188 related articles for article (PubMed ID: 25638254)
1. Effects of GRK5 and ADRB1 polymorphisms influence on systolic heart failure.
Kang S; Hong X; Ruan CW; Yu P; Yu SS; Chen M; Zhang DF; Fan HM; Liu ZM
J Transl Med; 2015 Feb; 13():44. PubMed ID: 25638254
[TBL] [Abstract][Full Text] [Related]
2. Clinical and genetic modifiers of long-term survival in heart failure.
Cresci S; Kelly RJ; Cappola TP; Diwan A; Dries D; Kardia SL; Dorn GW
J Am Coll Cardiol; 2009 Jul; 54(5):432-44. PubMed ID: 19628119
[TBL] [Abstract][Full Text] [Related]
3. A GRK5 polymorphism that inhibits beta-adrenergic receptor signaling is protective in heart failure.
Liggett SB; Cresci S; Kelly RJ; Syed FM; Matkovich SJ; Hahn HS; Diwan A; Martini JS; Sparks L; Parekh RR; Spertus JA; Koch WJ; Kardia SL; Dorn GW
Nat Med; 2008 May; 14(5):510-7. PubMed ID: 18425130
[TBL] [Abstract][Full Text] [Related]
4. GRK5 Gln41Leu polymorphism is not associated with sensitivity to beta(1)-adrenergic blockade in humans.
Kurnik D; Cunningham AJ; Sofowora GG; Kohli U; Li C; Friedman EA; Muszkat M; Menon UB; Wood AJ; Stein CM
Pharmacogenomics; 2009 Oct; 10(10):1581-7. PubMed ID: 19842931
[TBL] [Abstract][Full Text] [Related]
5. Associations between ADRB1 and CYP2D6 gene polymorphisms and the response to β-blocker therapy in hypertension.
Wu D; Li G; Deng M; Song W; Huang X; Guo X; Wu Z; Wu S; Xu J
J Int Med Res; 2015 Jun; 43(3):424-34. PubMed ID: 25823457
[TBL] [Abstract][Full Text] [Related]
6. The Association of ADRB1 and CYP2D6 Polymorphisms With Antihypertensive Effects and Analysis of Their Contribution to Hypertension Risk.
Chen L; Xiao T; Chen L; Xie S; Deng M; Wu D
Am J Med Sci; 2018 Mar; 355(3):235-239. PubMed ID: 29549925
[TBL] [Abstract][Full Text] [Related]
7. Synergistic polymorphisms of beta1 and alpha2C-adrenergic receptors and the influence on left ventricular ejection fraction response to beta-blocker therapy in heart failure.
Lobmeyer MT; Gong Y; Terra SG; Beitelshees AL; Langaee TY; Pauly DF; Schofield RS; Hamilton KK; Herbert Patterson J; Adams KF; Hill JA; Aranda JM; Johnson JA
Pharmacogenet Genomics; 2007 Apr; 17(4):277-82. PubMed ID: 17496726
[TBL] [Abstract][Full Text] [Related]
8. Effects of sex and the common ADRB1 389 genetic polymorphism on the hemodynamic response to dobutamine.
Yogev D; Basheer M; Blotnick S; Caraco Y; Muszkat M
Pharmacogenet Genomics; 2015 Nov; 25(11):555-63. PubMed ID: 26313487
[TBL] [Abstract][Full Text] [Related]
9. Adrenergic-pathway gene variants influence beta-blocker-related outcomes after acute coronary syndrome in a race-specific manner.
Cresci S; Dorn GW; Jones PG; Beitelshees AL; Li AY; Lenzini PA; Province MA; Spertus JA; Lanfear DE
J Am Coll Cardiol; 2012 Sep; 60(10):898-907. PubMed ID: 22703928
[TBL] [Abstract][Full Text] [Related]
10. ADRB1 and ADBR2 gene polymorphisms and the ocular hypotensive response to topical betaxolol in healthy Mexican subjects.
Messina Baas O; Pacheco Cuellar G; Toral-López J; Lara Huerta SF; Gonzalez-Huerta LM; Urueta-Cuellar H; Rivera-Vega MR; Babayan-Mena I; Cuevas-Covarrubias SA
Curr Eye Res; 2014 Nov; 39(11):1076-80. PubMed ID: 24749907
[TBL] [Abstract][Full Text] [Related]
11. Lack of genetic susceptibility in takotsubo cardiomyopathy: a case-control study.
Mattsson E; Saliba-Gustafsson P; Ehrenborg E; Tornvall P
BMC Med Genet; 2018 Mar; 19(1):39. PubMed ID: 29514624
[TBL] [Abstract][Full Text] [Related]
12. Relation of ADRB1, CYP2D6, and UGT1A1 polymorphisms with dose of, and response to, carvedilol or metoprolol therapy in patients with chronic heart failure.
Baudhuin LM; Miller WL; Train L; Bryant S; Hartman KA; Phelps M; Larock M; Jaffe AS
Am J Cardiol; 2010 Aug; 106(3):402-8. PubMed ID: 20643254
[TBL] [Abstract][Full Text] [Related]
13. Impact of the β-1 adrenergic receptor polymorphism on tolerability and efficacy of bisoprolol therapy in Korean heart failure patients: association between β adrenergic receptor polymorphism and bisoprolol therapy in heart failure (ABBA) study.
Lee HY; Chung WJ; Jeon HK; Seo HS; Choi DJ; Jeon ES; Kim JJ; Shin JH; Kang SM; Lim SC; Baek SH
Korean J Intern Med; 2016 Mar; 31(2):277-87. PubMed ID: 26879662
[TBL] [Abstract][Full Text] [Related]
14. The genetics of cardiac failure: Role of a G protein-coupled receptor polymorphism in therapeutic response in an Indian population.
Ramalingam S; Radhakrishnan S; Kaliappan T; Gopalan R; Subrahmanian M; Sankaran R
J Clin Transl Res; 2021 Aug; 7(4):501-510. PubMed ID: 34541364
[TBL] [Abstract][Full Text] [Related]
15. Beta2-adrenergic receptor genotype and survival among patients receiving beta-blocker therapy after an acute coronary syndrome.
Lanfear DE; Jones PG; Marsh S; Cresci S; McLeod HL; Spertus JA
JAMA; 2005 Sep; 294(12):1526-33. PubMed ID: 16189366
[TBL] [Abstract][Full Text] [Related]
16. Lack of association between adrenergic receptor genotypes and survival in heart failure patients treated with carvedilol or metoprolol.
Sehnert AJ; Daniels SE; Elashoff M; Wingrove JA; Burrow CR; Horne B; Muhlestein JB; Donahue M; Liggett SB; Anderson JL; Kraus WE
J Am Coll Cardiol; 2008 Aug; 52(8):644-51. PubMed ID: 18702968
[TBL] [Abstract][Full Text] [Related]
17. Arg389Gly-beta1-adrenergic receptors determine improvement in left ventricular systolic function in nonischemic cardiomyopathy patients with heart failure after chronic treatment with carvedilol.
Chen L; Meyers D; Javorsky G; Burstow D; Lolekha P; Lucas M; Semmler AB; Savarimuthu SM; Fong KM; Yang IA; Atherton J; Galbraith AJ; Parsonage WA; Molenaar P
Pharmacogenet Genomics; 2007 Nov; 17(11):941-9. PubMed ID: 18075464
[TBL] [Abstract][Full Text] [Related]
18. β1 adrenergic receptor polymorphisms and heart failure: a meta-analysis on susceptibility, response to β-blocker therapy and prognosis.
Liu WN; Fu KL; Gao HY; Shang YY; Wang ZH; Jiang GH; Zhang Y; Zhang W; Zhong M
PLoS One; 2012; 7(7):e37659. PubMed ID: 22815685
[TBL] [Abstract][Full Text] [Related]
19. Effect of specific ADRB1/ADRB2/AGT genotype combinations on the association between survival and carvedilol treatment in chronic heart failure: a substudy of the ECHOS trial.
Petersen M; Andersen JT; Jimenez-Solem E; Broedbaek K; Afzal S; Nyegaard M; Børglum AD; Stender S; Torp-Pedersen C; Køber L; Poulsen HE
Pharmacogenet Genomics; 2012 Oct; 22(10):709-15. PubMed ID: 22760495
[TBL] [Abstract][Full Text] [Related]
20. Effects of polymorphisms in beta1-adrenoceptor and alpha-subunit of G protein on heart rate and blood pressure during exercise test. The Finnish Cardiovascular Study.
Nieminen T; Lehtimäki T; Laiho J; Rontu R; Niemelä K; Kööbi T; Lehtinen R; Viik J; Turjanmaa V; Kähönen M
J Appl Physiol (1985); 2006 Feb; 100(2):507-11. PubMed ID: 16210433
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
